Cancer Program

Susanna M. Hamilton, Ó³»­´«Ã½ Communications

The study of structural variation — large-scale changes in DNA that can, in some cases, refashion entire chromosomes — in the genomic era has lagged behind that of sequence variation. But there’s a growing appreciation of how important structural variants are to human biology and disease. What makes these variants more challenging to study, and what is being done to overcome those challenges?

Corrie Painter, associate director of operations and scientific outreach at the Ó³»­´«Ã½ and one of the creators of The Metastatic Breast Cancer Project, and Eliezer Van Allen, an oncologist at Dana Farber Cancer Institute and an associate member at Ó³»­´«Ã½, discuss patient engagement, which is critical for advancing our understanding of both common and rare cancers and empowering people to get in the driver's seat of clinical research.

Ó³»­´«Ã½ cancer research includes efforts to decipher the genetic and molecular landscape of a wide range of cancer and immune cells as well as equally systematic genome-wide approaches to interrogate the function of cancer genes and the vulnerabilities of tumors. In partnership with colleagues within academia and industry, Ó³»­´«Ã½ cancer researchers develop breakthrough technologies to drive discoveries of new drug targets and potential therapies, and generate systematic strategies for predicting therapeutic combinations to combat resistance.